This business information is not released now.


Back
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.


GreenPeptide Co., Ltd.
【Field/Business】
Pharmaceutical/Drug Discovery


last update:2017/12/11
Profile

Delegates :
President & CEO Kenichi Nagai


Incorporated :
May   8 , 2003

Paid in Capital :
3774 Million yen  Increased due IPO and financing after IPO

Employees :
37 人

Address :
1-1 Hyakunen Koen, Kurume, Fukuoka,839-0864,JAPAN FUKUOKA
〒839-0083

TEL/FAX :
+81-942-38-6550 / +81-942-38-6564

URL:
http://www.green-peptide.com

Attachment :

Mission/Background :
GreenPeptide is a drug discovery venture company responsible for the development of innovative “cancer immunotherapy” as the 4th cancer treatment following surgery, radiotherapy, and chemotherapy. Clinical trials on cancer peptide vaccines are being conducted in Japan and the United States, and we recently started the development of new T-cell therapy involving the iPS regeneration of antigen-specific T cells. We have also announced the development of new drugs using neoantigens, which is a highly novel approach in the world.

Technology & Business
Our cancer peptide vaccine uses an adjuvanted, peptide-based approach to enhance an existing anti-cancer immune response. Based on our hypothesis that treating patients with a personalized anti-peptide immunization regimen to enhance an existing anti-tumoral cellular immune response will eradicate tumors and increase patient survival, the selective immunogens tailored for each patient, up to 4 peptides showing the highest humoral immune response tested prior to the administration, are selected for vaccination out of 12 peptide pool derived from multi-tumor antigens.
Addition to the above, we recently started the development of new T-cell therapy involving the iPS regeneration of antigen-specific T cells. We have also announced the development of new drugs using neoantigens, which is a highly novel approach in the world.

Products & Service
Products & Service Name
Stage
Outline
Milestone
ITK-1
Phase3
HRPC
Finalising Phase V and key-open
GRN-1201
Phase2
Same concept of ITK-1. Conducting in the U.S. Indications are Melanoma and Non-small cell lung cancer
To acquire effective data regarding concomitant use of an immune checkpoint antibody with a cancer vaccine












Highlights
(ITK-1)
Jun 2015 Performed interim analysis in a phase III clinical trials of ITK-1 in castration-resistant
prostate cancer.
Apr 2016 Finished the enrollment of patients.
(GRN-1201)
Oct 2015 Start of phase I clinical trials of GRN-1201 for malignant melanoma in the U.S.
Jan 2017 Start of phase II clinical trials of GRN-1201 with the concomitant use of an immune checkpoint
antibody against non-small cell lung cancer in the U.S.
Hot news

Alliance strategy
GreenPeptide is seeking alliance partners to co-develop in Japan and globally especially in regard to cancer immunotherapy.

 
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.